BridgeBio Confirms Global Interest in Idiopathic Pulmonary Fibrosis Treatment Candidate

Specific Negotiations Underway for Technology Transfer Contract

New drug research and development company Bridge Biotherapeutics introduced business prospects centered on the idiopathic pulmonary fibrosis treatment candidate BBT-877.

On the 16th (local time), Lee Jung-kyu, CEO of Bridge Biotherapeutics, announced at JPMHC. Bridge Biotherapeutics

On the 16th (local time), Jeong-gyu Lee, CEO of Bridge Biotherapeutics, stated at the JP Morgan Healthcare Conference held in San Francisco, USA, "This JP Morgan Healthcare Conference was an opportunity to confirm the global companies' interest in the idiopathic pulmonary fibrosis treatment candidate 'BBT-877'."

Bridge Biotherapeutics was invited by JP Morgan for the first time this year and was selected as an on-site presenting company.

Idiopathic pulmonary fibrosis is an intractable disease in which collagen abnormally accumulates in the lungs, causing loss of lung function. It is known that the survival rate is only 40% five years after diagnosis. BBT-877 is in the final stages of global Phase 2 clinical trials.

CEO Lee said, "Looking at the latest progress of the Phase 2 clinical trial, promising safety levels and potential for lung function recovery are expected," adding, "The incidence of diarrhea, a representative side effect mentioned when taking standard idiopathic pulmonary fibrosis drugs, was recorded at about 8.5% as of the end of December last year, which appears to be lower than that of competing drugs."

He also mentioned the plan for a Phase 3 clinical trial of BBT-877, which involves administering the drug for 52 weeks to more than 1,000 idiopathic pulmonary fibrosis patients. This clinical trial will be conducted in collaboration with global big pharma, aiming to enter the trial phase in the first half of next year.

He also reported that specific negotiations for a technology transfer contract for BBT-877 were conducted during the conference. He said, "Throughout the event, I felt the growing interest of major global pharmaceutical and bio companies in the Korea-based innovative new drug BBT-877," and added, "We will do our best to showcase achievements in signing a global technology transfer contract."

This content was produced with the assistance of AI translation services.